Wells Fargo Beefs Up Kezar Life Price Target - Read Why

  • Wells Fargo reiterated its Overweight rating and raised its price target to $17 from $13 for Kezar Life Sciences Inc KZR on zetomipzomib's (zeto) positive Ph2 MISSION data in lupus nephritis (LN). 
  • The analysts say that the data is in-line with our bull case and well ahead of Street expectations since PRESIDIO's failure. 
  • Wells Fargo says the high complete renal response/overall renal response, the durability of effect, and meaningful reductions in steroids in the study validate zeto as an active agent in LN. 
  • They see a peak sales opportunity of approximately $1 billion. KZR plans to discuss zeto's next steps in LN with the FDA later this year.
  • "We think the "dream the dream" scenario is still alive for zeto as the co plans to explore additional indications, which may include systemic lupus erythematosus (SLE)." Wells Fargo notes.
  • The analysts think zeto's data is even more impressive given its ~35% CRR is with lower starting doses of MMF and lower/declining doses of steroids.
  • 11 of 17 patients (64.7%) achieved an ORR measured, the primary efficacy endpoint of the clinical trial.
  • Price Action: KZR shares are up 43.90% at $8.32 during the market session on the last check Tuesday.

Posted In: BriefsAnalyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.